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Abstract
OBJECTIVE: To justify the clinical use of Traditional
Chinese Medicine (TCM) in the treatment of influen-
za.
METHODS: MEDLINE, EMBASE, Chinese Biomedical
Literature Database, China National KnowledgeIn-
frastructure Database, China Science and Technolo-
gy Journal Database, Wanfang Database and the
Cochrane Database of Systematic Reviews were
searched from thedate of inception until January 1,
2013, for the literature on treatment of influenza
with TCM.
RESULTS: A total of 7 randomized controlled trials
were identified and reviewed. Of these trials, 2 com-
pared a (modified) prescription of TCM with oselta-
mivir and 5 compared a patent traditional Chinese
drug with oseltamivir. Based on the Meta-analysis,
compared to oseltamivir, the (modified) prescrip-
tion had similar effect in defervescence [WMD=
5.66, 95% CI (﹣32.02, 43.35), P=0.77] and viral shed-
ding [WMD=﹣ 6.21, 95% CI (﹣ 84.19, 71.76), P=
0.88], and the patent traditional Chinese drug also
had similar effect in viral shedding [WMD=﹣0.24,
95% CI (﹣4.79, 4.31), P=0.92] but more effective in
defervescence [WMD=﹣4.65, 95%CI (﹣8.91,﹣0.38),
P=0.03].
CONCLUSION: TCM has potential positive effects in
the treatment of influenza.
© 2014 JTCM. All rights reserved.
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INTROCTION
Up to now, the threat of pandemic influenza remains
an internationally major public healthconcern.1 As an
important pharmaceutical intervention against the in-
fluenza virus, oseltamivir has been widely used against
influenza virus infection in the world.2 It has been dem-
onstrated that oseltamivir can prevent the release of
progeny viral particles from infected host cells and
shorten the duration of influenza and decrease the de-
velopment of serious complications.3,4 However, a ma-
jor shortcoming of oseltamivir is the emergency of viral
resistance.5 Therefore, it is of crucial importance to find
an effective and safety alternative to treat influenza in-
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fection, especially in rural areas of China where the
supply of oseltamivir is often insufficient.
In China, Traditional Chinese Medicine (TCM) with a
history of thousands of years is proved to be effective
for the treatment of infectious diseases.6 Some studies
have demonstrated that TCM can be used as an alterna-
tive treatment of influenza virus infection.7-9 In this
study, the clinical effectof TCM in the treatment of in-
fluenza A virus infection is evaluated through compari-
son with oseltamivir.
METHODS
Search strategy
MEDLINE, EMBASE, Chinese Biomedical Literature
Database (CBM), China National KnowledgeInfra-
structure Database (CNKI), China Science and Tech-
nology Journal Database (VIP), Wanfang Database and
the Cochrane Database of Systematic Reviews were
searched from thedate of inception until January 1,
2013. Of these databases, CBM, CNKI, Chinese Scien-
tific Journal Database and Wanfang Database provided
literaturesin Chinese. In this study, "Traditional Chi-
nese Medicine", "oseltamivir" and "influenza" were de-
signed for the search. Reference lists from retrieved doc-
uments were also searched.
Criteria of inclusion
Subjects older than 3 years and hospitalized with a clin-
ical or laboratory diagnosis of influenza infection were
included in this study. Other inclusion criteria were:
(a) study design: randomized controlled trial; (b) inter-
vention: treatment group with a relatively fixed pre-
scription of TCM or a patent traditional Chinese drug
and control group with oseltamivir; (c) human studies.
Quality control
Data were independently extracted from each studyus-
ing pre-defined forms by two investigators, and dis-
agreement was resolved by discussionamong investiga-
tors and reference to the original article. When several
publications pertaining to a single study were identi-
fied, the most complete publication was used. The con-
crete assessments were seen in the article10 (Jadad score).
Efficacy measures
Efficacy was measured with duration of fever and viral
shedding. The safety of treatment was also assessed.
Data analysis
Data analysis was carried out using Review Manager
Software 4.211 (Cochrane Collaboration, Oxford, Unit-
ed Kingdom). The effect measures estimated were
weighted mean difference (WMD), reported with 95%
confidence intervals (CI). Fixed-effect or random-effect
method in the analysis depended on the absence or
presence of significant heterogeneity which was evaluat-
ed by the Chi-square and I-square (I2) tests. In the ab-
sence of statistically significant heterogeneity, the
fixed-effect method was used to combine the results.
When heterogeneity was confirmed, the random-effect
method was used. The overall effect was tested using Z
scores, with significance set at P<0.05.
RESULTS
Selection and characteristics of study
Searches resulted in 2132 unique articles. Finally, 7 ran-
domized controlled trials (RCTs) were left for analy-
sis.12-18 Figure 1 shows the flow chart of study selection
process. 2 trials compared the efficacies between (modi-
fied) Yinqiao powder and oseltamivir and the total
number of patients involved was 93.5 trials compared
the efficacies between Lianhuaqingwen capsule and os-
eltamivir and the total number of patients involved
was 607. Table 1 summarizes the main characteristics
of the included studies.
Clinical outcomes
Comparison of the effect of Yinqiao powder with osel-
tamivir: 2 trials in which the effect of Yinqiao powder
2132 studies identified through database searching
1828 excluded after title review (not eligible for this analysis)
304 abstracts screened
255 excluded after abstract review (not eligible for the analysis)
49 full-text articles screened
Reasons for exclusion after full-text review:
not a randomized controlled trial (13);
great differences in the prescription of
Traditional Chinese Medicine (12);
lack of relevant data (17).
7 eventually included in the meta analysis
Figure 1 Flowchart of study selection process
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on influenza was compared with oseltamivir were in-
cluded in the analysis.12,13 There was no statistical differ-
ence between the two groups in duration of fever
[WMD=5.66, 95% CI (﹣32.02, 43.35), P=0.77] or in
duration from onset to negativity of viral RNA
[WMD=﹣6.21, 95% CI (﹣84.19, 71.76), P=0.88].
Figure 2 shows the forest plot of effect comparison of
Yinqiao powder versus oseltamivir.
Comparison of the effect of Lianhuaqingwen capsule-
with oseltamivir: 5 trials in which the effect of Lian-
huaqingwen capsule on influenzawere compared with
oseltamivir were included in the analysis.14-18 Shorter fe-
ver duration was shown in the Lianhuaqingwen capsule
group as compared with that in the oseltamivir group,
witha statistically significant difference between the
two groups [WMD=﹣4.65, 95%CI (﹣8.91,﹣0.38),
P=0.03]. Regarding the viral shedding, there was no
statistical difference between the two groups in dura-
tion from onset to negativity of viral RNA [WMD=﹣
0.24, 95% CI (﹣4.79, 4.31), P=0.92]. Figure 3 shows
the forest plot of effect comparison of Lianhuaqingwen
capsule versus oseltamivir.
Safety: in the included patients treated with Yinqiao
powder, Lianhuaqingwen capsule or oseltamivir, no sig-
nificant drug-related serious adverseevents such as neu-
ropsychiatric events, including delirium and abnormal
behavior, were reported.
DISCUSSION
As an alternative therapy, TCM focuses on the treat-
ment of human disease via the integrity of the close re-
lationship between body and syndrome analysis and be-
comes increasingly more popular worldwide because of
its"miraculous" curative effect.19 Yinqiao powder is a
traditional Chinese prescription mainly composed of
Jinyinhua (Flos Lonicerae), Lianqiao (Fructus Forsythiae
Suspensae), Bohe (Herba Menthae Haplocalycis), et al.
Lianhuaqingwen capsule is a Chinese patent medicine
composed of honey-fried Mahuang (Herba Ephedra Si-
nica), Kuxingren (Semen Armeniacae Amarum), Lianqiao
Study
Zhang WS et al 201112
Zheng HP et al 201013
Duan ZP et al 201114
Ma YP et al 201015
Liu GX et al 201016
Li BF et al 200917
Geng LM et al 201118
Sample and intervention
Treatment group
30 cases were treated with (modified)
Yinqiao powder
14 cases were treated with (modified)
Yinqiao powder
122 cases were treated with
Lianhuaqingwen capsule
60 cases were treated with Lianhuaqingwen
capsule
64 cases were treated with Lianhuaqingwen
capsule
25 cases were treated with Lianhuaqingwen
capsule
38 cases were treated with Lianhuaqingwen
capsule
Control group
30 cases were treated with
oseltamivir
19 cases were treated with
oseltamivir
122 cases were treated
with oseltamivir
74 cases were treated with
oseltamivir
60 cases were treated with
oseltamivir
25 cases were treated with
oseltamivir
30 cases were treated with
oseltamivir
Study design
RCT, blind
unclear
RCT, blind
unclear
RCT, dou-
ble-blind
RCT, blind
unclear
RCT, blind
unclear
RCT, dou-
ble-blind
RCT, blind
unclear
Jadad
score
2
2
5
2
2
3
2
Table 1 Main characteristic of the included trials
Note: RCT: randomized controlled trials.
Figure 2 Forest plot of effect comparison of Yinqiao powder vs oseltamivir on the time to defervescence
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(Fructus Forsythiae Suspensae), Bohe (Herba Menthae
Haplocalycis), et al. Because the mechanism of TCM in
the treatment of influenza is complex, it is difficult to
determine which ingredient plays the main roles in an-
ti-influenza virus infection. However, it is well known
that some Chinese herbs can suppress the viral replica-
tion and may have beneficial immunomodulatory ef-
fects for rapid recovery of viral infections.20-22
Based on the outcomes from our Meta-analysis, the
(modified) Yinqiao powder had similar effect with osel-
tamivir in defervescence and viral shedding; the pa-
tients treated with Lianhuaqingwen capsule had short-
er duration of fever than the patients treated with osel-
tamivir and the efficacy of the two treatments on viral
shedding was similar. Some severe adverse events were
not observed in both the two groups in our included
studies, though these events had been reportedin
post-marketing surveillance for oseltamivir.23 Concern-
ing the adverse effect, we found that the report from
most of the included studies was inadequate, which
was a major limitation of our study.
In conclusion, compared to oseltamivir, TCM has po-
tential positive effect in the treatment of influenza.
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